A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)

March 24, 2023 updated by: Hoffmann-La Roche

An Open-Label, Multicenter, Rollover Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease

This is an open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term administration of open-label gantenerumab in participants with AD who completed Study WN29922 or WN39658, either the double-blind or open-label extension (OLE) part.

Study Overview

Status

Terminated

Conditions

Detailed Description

Participants who were in the active arm in the double blind part and those who have completed OLE part in the parent study, will continue receive open-label gantenerumab 510 mg sub-cutaneously (SC) every 2 weeks (Q2W). Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme as in the parent study before receiving target dose of open label gantenerumab.

Study Type

Interventional

Enrollment (Actual)

1379

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Caba, Argentina, C1199ABB
        • Hospital Italiano
      • Caba, Argentina, C1405BCK
        • Universidad Maimonides
      • Capital Federal, Argentina, C1427CCP
        • Instituto Geriatrico Nuestra Señora de Las Nieves
      • Cordoba, Argentina, X5004FJF
        • CEN Centro Especializado en Neurociencias
      • Córdoba, Argentina, X5004AOA
        • Instituto Kremer
      • La Plata, Argentina, B1902AVF
        • Instituto de Neurociencias San Agustín S.A.
      • Mendoza, Argentina, M5500AYB
        • Fundación Scherbovsky; General Department
    • New South Wales
      • Darlinghurst, New South Wales, Australia, 2010
        • St Vincent's Hospital Sydney; Neurology
      • Erina, New South Wales, Australia, 2250
        • Central Coast Neurosciences Research
      • Kogarah, New South Wales, Australia, 2217
        • Southern Neurology
    • South Australia
      • Woodville, South Australia, Australia, 5011
        • The Queen Elizabeth Hospital; Neurology
    • Victoria
      • Heidelberg West, Victoria, Australia, 3081
        • Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Australian Alzheimer's Research Foundation
      • Dendermonde, Belgium, 9200
        • AZ Sint Blasius (Dendermonde)
      • Gent, Belgium, 9000
        • UZ Gent
      • Hasselt, Belgium, 3500
        • Jessa Zkh (Campus Virga Jesse)
    • PR
      • Curitiba, PR, Brazil, 81210-310
        • Instituto de Neurologia de Curitiba
      • Curitiba, PR, Brazil, 80810-040
        • Hospital Nossa Senhora das Graças; Setor de Pesquisa em Neurologia
      • Maringa, PR, Brazil, 87013-250
        • Clinica Clinilive Ltda
    • RS
      • Porto Alegre, RS, Brazil, 90035-903
        • Hospital das Clinicas - UFRGS
    • SP
      • Sao Paulo, SP, Brazil, 05403-000
        • Hospital das Clinicas - FMUSP_X; Neurologia
      • Quebec, Canada, G3K 2P8
        • ALPHA Recherche Clinique
    • British Columbia
      • Vancouver, British Columbia, Canada, V7T 2Z3
        • The Medical Arts Health Research Group - West Vancouver
    • Ontario
      • London, Ontario, Canada, N6C 5J1
        • Parkwood Hospital; Geriatric Medicine
      • Toronto, Ontario, Canada, M4N 3M5
        • SunnyBrook Health Sciences Centre
      • Toronto, Ontario, Canada, M6A 2E1
        • Baycrest Health Sciences
      • Woodstock, Ontario, Canada, N4S 5P5
        • Devonshire Clinical Research
    • Quebec
      • Greenfield Park, Quebec, Canada, J4V 2J2
        • Center for Diagnosis and Research on Alzheimer's disease
      • Antofagasta, Chile, 1270244
        • Psicomed Estudios Medicos
      • Santiago, Chile, 7500710
        • BioMedica Research Group
      • Santiago, Chile, 7560356
        • Especialidades Medicas LYS
      • Beijing City, China, 100071
        • Beijing Tian Tan Hospital,Capital Medical University
      • Aarhus N, Denmark, 8200
        • Aarhus Universitetshospital; Neurologisk Afd. F, Demensklinikken
      • Koebenhavn Oe, Denmark, 2100
        • Rigshospitalet, Hukommelsesklinikken
      • Svendborg, Denmark, 5700
        • Svendborg Sygehus; Neurologisk afdeling N, Demensklinik Fyn
      • Helsinki, Finland, 00180
        • Terveystalo Ruoholahti
      • Kuopio, Finland, 70210
        • Itä-Suomen yliopisto, Kuopion kampus
      • Amiens Cedex1, France, 80054
        • CHU Amiens Hopital Sud; Neurologie
      • Bobigny Cedex, France, 93009
        • Hôpital Avicenne; Centre de Recherche Clinique
      • Bron cedex, France, 69677
        • Groupement Hospitalier Est - Hôpital Neurologique; Neurologie A (U502)
      • Marseille, France, 13005
        • CHU de la Timone - Hopital d Adultes; Service de Neurologie
      • Paris, France, 75010
        • Hôpital Lariboisière
      • Poitiers, France, 86000
        • CHU Poitiers - Hôpital la Milétrie
      • Strasbourg, France, 67098
        • CHU Strasbourg Hôpital Hautepierre
      • Toulouse, France, 31059
        • Gerontopole; Centre de Recherche clinique
      • Villeurbanne, France, 69100
        • Hôpital des charpennes
      • Berlin, Germany, 13125
        • ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic
      • Berlin, Germany, 12200
        • Ambulates Gesundheitszentrum der Charité GmbH; MVZ Neurologie Campus Benjamin Franklin
      • Köln, Germany, 50937
        • Universitätsklinikum Köln; Klinik und Poliklinik für Psychiatrie und Psychotherapie
      • Leipzig, Germany, 04275
        • PANAKEIA - Arzneimittelforschung Leipzig GmbH
      • Mainz, Germany, 55131
        • Universitätsmedizin derJohannes Gutenberg-Universität Mainz;Klinik für Psychiatrie und Psychotherapi
      • München, Germany, 81675
        • Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie
      • Münster, Germany, 48149
        • Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie
      • Rostock, Germany, 18147
        • Universitätsklinikum Rostock Zentrum für Nervenheilkunde
      • Ulm, Germany, 89081
        • Universitätsklinikum Ulm; Klinik für Neurologie
      • Westerstede, Germany, 26655
        • Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz
      • Witten, Germany, 58455
        • Forschungszentrum Ruhr
      • Budapest, Hungary, 1083
        • Semmelweis University; Department of Neurology
    • Emilia-Romagna
      • Modena, Emilia-Romagna, Italy, 41126
        • Nuovo Ospedale Civile S. Agostino-Estense; Clinica Neurologica ? Dipartimento di Neuroscienze
    • Lazio
      • Roma, Lazio, Italy, 00185
        • Umberto I Policlinico di Roma-Università di Roma La Sapienza
      • Roma, Lazio, Italy, 00186
        • Ospedale San Giovanni Calibita Fatebenefratell;Neurologia
      • Roma, Lazio, Italy, 00179
        • Fondazione Santa Lucia IRCCS; Neurologia e Riabilitazione Neurologica
    • Lombardia
      • Brescia, Lombardia, Italy, 25125
        • IRCCS ?Centro S. Giovanni di Dio? Fatebenefratelli -UO Alzheimer
      • Milano, Lombardia, Italy, 20132
        • IRCCS Ospedale San Raffaele; Centro Disturbi della Memoria
      • Monza, Lombardia, Italy, 20900
        • ASST DI MONZA; Neurologia
    • Molise
      • Pozzilli, Molise, Italy, 86077
        • IRCCS Neuromed; Neurologia I-Centro studio e cura delle demenze e UVA
    • Piemonte
      • Torino, Piemonte, Italy, 10126
        • AO Città della Salute e della Scienza Osp.S.Giov.Battista Molinette; SC Geriatria
    • Sicilia
      • Palermo, Sicilia, Italy, 90127
        • Dipartimento delle Patologie Emergenti; Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
      • Aichi, Japan, 446-8510
        • Yachiyo Hospital
      • Aichi, Japan, 454-8502
        • Nagoya Ekisaikai Hospital
      • Aichi, Japan, 474-8511
        • National Center for Geriatrics and Gerontology
      • Chiba, Japan, 260-8656
        • Medical Corporation Hakuyokai Kashiwado Hospital
      • Chiba, Japan, 261-0024
        • Tokyo Bay Advanced Medical and Makuhari Clinic
      • Chiba, Japan, 263-0043
        • Inage Neurology and Memory Clinic
      • Chiba, Japan, 279-0021
        • Juntendo University Urayasu Hospital
      • Fukuoka, Japan, 814-0180
        • Fukuoka University Hospital
      • Fukushima, Japan, 963-8052
        • Southern Tohoku Medical Clinic
      • Hiroshima, Japan, 739-0696
        • National Hospital Organization Hiroshima-Nishi Medical Center
      • Hyogo, Japan, 650-0017
        • Kobe University Hospital
      • Hyogo, Japan, 670-8560
        • Hyogo Prefectural HarimaHimeji General Medical Center
      • Hyogo, Japan, 671-1227
        • Tsukazaki Hospital
      • Hyogo, Japan, 673-0891
        • Matsui Dietary and Dementia Clinic
      • Kagawa, Japan, 760-8557
        • Kagawa Prefectural Central Hospital
      • Kanagawa, Japan, 223-0059
        • Yuai Clinic
      • Kanagawa, Japan, 247-8533
        • Shonan Kamakura General Hospital
      • Kyoto, Japan, 607-8062
        • Rakuwakai Otowa Hospital
      • Kyoto, Japan, 611-0021
        • Uji Takeda Hospital
      • Niigata, Japan, 940-2302
        • Mishima Hospital
      • Okayama, Japan, 703-8265
        • Okayama Kyokuto Hospital
      • Okayama, Japan, 710-0813
        • Rijikai Medical Corporation Katayama Medical Clinic
      • Osaka, Japan, 560-0004
        • MI Clinic
      • Osaka, Japan, 596-0042
        • Kishiwada Tokushukai Hospital
      • Saga, Japan, 842-0192
        • National Hospital Organization Hizen Psychiatric Medical Center
      • Shizuoka, Japan, 420-8688
        • NHO Shizuoka Institute of Epilepsy and Neurological Disorders
      • Shizuoka, Japan, 424-0911
        • Shizuoka City Shimizu Hospital
      • Tochigi, Japan, 329-0403
        • Jichiidai Station Brain Clinic
      • Tokushima, Japan, 770-0852
        • Medical corporation Ichiekai Itsuki Hospital
      • Tokushima, Japan, 776-8585
        • Tokushima Hospital
      • Tokyo, Japan, 187-8551
        • National Center of Neurology and Psychiatry
      • Tokyo, Japan, 160-0023
        • Tokyo Medical University Hospital
      • Tokyo, Japan, 113-8519
        • Tokyo Medical and Dental University Hospital
      • Tokyo, Japan, 181-0013
        • Nozomi Memory Clinic
      • Tokyo, Japan, 192-0071
        • P-one Clinic
      • Yamagata, Japan, 990-0834
        • Yamagata Tokusyukai Hospital
      • Busan, Korea, Republic of, 49201
        • Dong-A University Hospital
      • Gyeonggi-do, Korea, Republic of, 10475
        • Myongji Hospital
      • Incheon, Korea, Republic of, 21565
        • Gachon University Gil Medical Center
      • Incheon, Korea, Republic of, 22332
        • Inha University Hospital
      • Seongnam-si, Korea, Republic of, 13620
        • Seoul National University Bundang Hospital
      • Seoul, Korea, Republic of, 135-710
        • Samsung Medical Center
      • Seoul, Korea, Republic of, 05030
        • Konkuk University Medical Center
      • Seoul, Korea, Republic of, 05505
        • Asan Medical Center
      • Seoul, Korea, Republic of, 04763
        • Hanyang University Seoul Hospital
      • Seoul, Korea, Republic of, 06591
        • Seoul St Mary's Hospital
      • Seoul, Korea, Republic of, 07804
        • Ewha Womans University Hospital (Seoul)
      • Vilnius, Lithuania, 08661
        • Vilnius University Hospital Santariskiu Clinics; Neurology
      • Culiacan, Mexico, 80020
        • Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC
      • Monterrey, Mexico, 64460
        • Hospital Universitario Dr Jose Eleuterio Gonzalez UANL; Depto.de NeurologíaPta.BajaConsulta
      • Monterrey, Mexico, 64710
        • AVIX Investigación Clínica S.C
    • Mexico CITY (federal District)
      • Ciudad de México, Mexico CITY (federal District), Mexico, 03100
        • Mexico Centre for Clinical Research
      • Amsterdam, Netherlands, 1081 GN
        • Brain Research Center B.V
      • Bellavista, Peru, Callao 2
        • Hospital IV Alberto Sabogal Sologuren; Unidad de Investigacion
      • Lima, Peru, 15001
        • Clinica Internacional; Unidad De Investigacion
      • Lima, Peru, 15003
        • Hospital Nacional Dos de Mayo; Unidad de Investigacion de Neurologia
      • ?cinawa, Poland, 59-330
        • O?rodek Badawczo-Naukowo-Dydaktyczny Chorób Ot?piennych w ?cinawie
      • Bia?ystok, Poland, 15-756
        • Podlaskie Centrum Psychogeriatrii
      • Bydgoszcz, Poland, 85-079
        • NZOZ Vitamed
      • Lublin, Poland, 20-362
        • KO-MED Centra Kliniczne Lublin II
      • Plewiska, Poland, 62-064
        • Neurologiczny NZOZ Centrum Leczenia SM; Osrodek Badan Klinicznych
      • Siemianowice ?l?skie, Poland, 41-100
        • Neuro-Care Sp. z o.o. Sp. Komandytowa
      • Sopot, Poland, 81-855
        • Senior Sp. Z O.O. Poradnia Psychogeriatryczna
      • Warszawa, Poland, 01-684
        • mMED Maciej Czarnecki
      • Warszawa, Poland, 01-868
        • Pratia S.A.
      • Wroc?aw, Poland, 53-659
        • NZOZ WCA
      • Braga, Portugal, 4710-243
        • Hospital de Braga; Servico de Neurologia
      • Coimbra, Portugal, 3000-075
        • HUC; Servico de Neurologia
      • Guimarães, Portugal
        • Hospital da Senhora da Oliveira-Guimarães; Serviço de Neurologia
      • Porto, Portugal, 4099-001
        • Hospital Geral de Santo Antonio; Servico de Neurologia
      • Bayamon, Puerto Rico, 00961
        • Santa Cruz Behavioral PSC
      • San Juan, Puerto Rico, 00936
        • University of Puerto Rico - Medical Science Campus; Internal Medicine
      • Kazan, Russian Federation, 420101
        • State autonomous institution of healthcare Inter-regional clinical and diagnostic center
      • Moscow, Russian Federation, 125101
        • City Clin Hosp n.a. S.P.Botkin
      • Sartatov, Russian Federation, 410028
        • MHI City Clinical Hospital #2 named after V.I. Razumovsky; Psychiatric
      • Tomsk, Russian Federation, 634009
        • Nebbiolo Center for Clinical Trials
    • Krasnojarsk
      • Krasnoyarsk, Krasnojarsk, Russian Federation, 660037
        • FSBHI Siberian Clinical Center of the Federal Medical and Biological Agency
    • Moskovskaja Oblast
      • Moscow, Moskovskaja Oblast, Russian Federation, 121467
        • University ?linic of headaches
      • Moskva, Moskovskaja Oblast, Russian Federation, 117556
        • City Polyclinic No. 2 of the Department of Healthcare of the City of Moscow
    • Sankt Petersburg
      • Sankt-peterburg, Sankt Petersburg, Russian Federation, 194044
        • FSBMEI HPE "Military Medical Academy n.a. S.M. Kirov" of the MoD of the RF
    • Tatarstan
      • Kazan, Tatarstan, Russian Federation, 420047
        • Vertebronevrologiya LLC
      • Albacete, Spain
        • Hospital General Universitario de Albacete; Servicio de Neurología
      • Barcelona, Spain, 08003
        • Hospital del Mar; Servicio de Neurologia
      • Barcelona, Spain, 08036
        • Hospital Clinic i Provincial; Servicio de Neurologia
      • Barcelona, Spain, 08041
        • Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia
      • Barcelona, Spain, 08028
        • Fundación ACE; Servicio de Neurología
      • Barcelona, Spain, 08035
        • Hospital Vall d'Hebron; Servicio de Neurología
      • Cordoba, Spain, 14004
        • Hospital Universitario Reina Sofia; Servicio de Neurologia
      • Madrid, Spain, 28041
        • Hospital Universitario 12 de Octubre; Servicio de Neurologia
      • Madrid, Spain, 28034
        • Hospital Ramon y Cajal; Servicio de Neurologia
      • Madrid, Spain, 28006
        • Universitario de La Princesa; Servicio de Neurología
      • Madrid, Spain, 28034
        • Hospital Ruber Internacional; Servicio de Neurología
      • Sevilla, Spain, 41013
        • Hospital Virgen del Rocío; Servicio de Neurología
      • Sevilla, Spain
        • Hospital Victoria Eugenia; Servico Neurología
      • Valencia, Spain, 46017
        • Hospital Universitario Dr. Peset; Servicio de Neurologia
      • Valencia, Spain, 46026
        • Hospital Universitario la Fe; Servicio de Neurologia
      • Zamora, Spain, 49021
        • Complejo Asistencial de Zamora; Servicio Psiquiatria
      • Zaragoza, Spain, 50012
        • Servicio de Neurología Hospital Viamed Montecanal.
    • Alicante
      • Elche, Alicante, Spain, 03203
        • Hospital General Universitario de Elche; Servicio de Neurología
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Spain, 08907
        • Hospital Universitari de Bellvitge; Servicio de Neurologia
      • Sant Cugat del Valles, Barcelona, Spain, 8195
        • Hospital General De Catalunya; Servicio de Neurologia
      • Terrassa, Barcelona, Spain, 08222
        • Hospital Mutua De Terrasa; Servicio de Neurologia
    • Caceres
      • Plasencia, Caceres, Spain, 10600
        • Hospital Virgen del Puerto. Servicio de Neurología
    • Cantabria
      • SANtander, Cantabria, Spain, 39011
        • Hospital Universitario Marques de Valdecilla; Servicio de Neurología
    • Guipuzcoa
      • Donostia-san Sebastian, Guipuzcoa, Spain, 20014
        • Policlínica Guipuzcoa; Servicio de Neurología
    • LA Rioja
      • Logroño, LA Rioja, Spain, 26006
        • Hospital San Pedro; Servicio de Neurología
    • Lerida
      • Lleida, Lerida, Spain, 25198
        • Hospital Universitario de Santa Maria; Servicio de Neurología
    • Madrid
      • Móstoles, Madrid, Spain, 28938
        • HM Universitario Puerta del Sur CINAC (C.Integ.Neuroc);; Servicio de Psiquiatría
      • Pozuelo de Alarcon, Madrid, Spain, 28223
        • Hospital Quiron de Madrid; Servicio de Neurologia
    • Navarra
      • Pamplona, Navarra, Spain, 31008
        • Clinica Universitaria de Navarra
      • Pamplona, Navarra, Spain, 31008
        • Clinica Universitaria de Navarra; Servicio de Neurología
    • Salamanca
      • Salamaca, Salamanca, Spain, 37007
        • Complejo Asistencial Universitario de Salamanca; Servicio de Psiquiatría
    • Vizcaya
      • Getxo, Vizcaya, Spain, 48993
        • CAE OROITU; Servicio de Neurología
      • Malmö, Sweden, 211 46
        • Skånes Universitetssjukhus Malmö, Minneskliniken
      • Mölndal, Sweden, 431 41
        • Sahlgrenska Academy University,Neuroscience and Physiology;Departmt of Psychiatry and Neurochemistry
      • Stockholm, Sweden, 141 86
        • KAROLINSKA UNI HOSPITAL, HUDDINGE; Mottagning Kognitiv Forskning, M54
      • Changhua County, Taiwan, 500
        • Changhua Christian Hospital; Neurology
      • Kaohsiung, Taiwan, 807
        • Kaohsiung Medical University Hospital; Neurology
      • Niaosong Dist., Taiwan, 83301
        • Chang Gung Memorial Foundation - Kaohsiung - Neurology
      • North Dist., Taiwan, 40447
        • China Medical University Hospital; Neurology
      • Taipei, Taiwan, 100
        • National Taiwan University Hospital; Neurology
      • Taoyuan, Taiwan, 333
        • Chang Gung Memorial Foundation - Linkou - Neurology
      • Samsun, Turkey, 55139
        • Ondokuz Mayis Univ. Med. Fac.; Neurology
      • Bath, United Kingdom, BA1 3NG
        • The Rice Centre; Royal United Hospital
      • Birmingham, United Kingdom, B16 8QQ
        • Re:Cognition Health Birmingham
      • Cheltenham, United Kingdom, GL53 9DZ
        • The Fritchie Centre, Charlton Lane Centre, Charlon Lane, Leckhampton; The Fritchie Centre
      • Chertsey, United Kingdom, KT16 9AU
        • Surrey and Borders NHS Foundation Trust; Research and Development Department
      • Dundee, United Kingdom, DD12 9SY
        • Ninewells Hospital
      • Glasgow, United Kingdom, G51 4TF
        • Queen Elizabeth University Hospital - PPDS
      • London, United Kingdom, W6 8RF
        • Charing Cross Hospital
      • London, United Kingdom, W1G 9RU
        • Re:Cognition Health London
      • London, United Kingdom, SW17 ORE
        • St George?s Hospital
      • Newcastle, United Kingdom, NE4 5PL
        • Campus for Ageing and Vitality
      • Sheffield, United Kingdom, S10 2JF
        • Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Foundation Trust
      • Southampton, United Kingdom, SO166YD
        • University Southampton NHS Foundation Trust; Wessex Neurologica Centre
    • Arizona
      • Phoenix, Arizona, United States, 85013
        • Barrow Neurological Institute
      • Phoenix, Arizona, United States, 85006
        • Banner Alzheimer?s Institute
      • Sun City, Arizona, United States, 85351
        • Banner Sun Health Research Insitute
    • Arkansas
      • Fayetteville, Arkansas, United States, 72703
        • Health Initiatives Research, PLLC
    • California
      • Fullerton, California, United States, 92835
        • Neurology Center of North Orange County
      • Fullerton, California, United States, 92835
        • Fullerton Neurology and Headache Center
      • Irvine, California, United States, 92614
        • Irvine Center for Clinical Research
      • Redlands, California, United States, 92374
        • Desert Valley Research
      • Sacramento, California, United States, 95816
        • Sutter Medical Group, Neurology
      • Santa Ana, California, United States, 92705
        • Syrentis Clinical Research
      • Sherman Oaks, California, United States, 91403
        • California Neuroscience Research Medical Group, Inc
      • Simi Valley, California, United States, 93065
        • Southern California Research LLC
    • Connecticut
      • New Haven, Connecticut, United States, 06519
        • Yale University School of Medicine
      • Norwalk, Connecticut, United States, 06851
        • Research Center for Clinical Studies, Inc.
    • District of Columbia
      • Washington, District of Columbia, United States, 20007
        • Georgetown University Medical Center
    • Florida
      • Atlantis, Florida, United States, 33462
        • JEM Research LLC
      • Bradenton, Florida, United States, 34205
        • Bradenton Research Center
      • Bradenton, Florida, United States, 34201
        • Accel Research Sites - CRU Tampa
      • Delray Beach, Florida, United States, 33445
        • Brain Matters Research, Inc.
      • Maitland, Florida, United States, 32751
        • ClinCloud, LLC
      • Miami, Florida, United States, 33155
        • Allied Biomedical Research Institute, Inc
      • Miami, Florida, United States, 33125
        • Optimus U Corp
      • Ocala, Florida, United States, 34470
        • Renstar Medical Research
      • Sarasota, Florida, United States, 34239
        • Intercoastal Medical Group
      • Sunrise, Florida, United States, 33351
        • Infinity Clinical Research, LLC
      • Tampa, Florida, United States, 33609
        • Axiom Clinical Research of Florida
      • Wellington, Florida, United States, 33414
        • Alzheimer?s Research and Treatment Center
    • Georgia
      • Atlanta, Georgia, United States, 30329
        • Emory University
      • Gainesville, Georgia, United States, 30501
        • Center for Advanced Research & Education
    • Illinois
      • Springfield, Illinois, United States, 62702
        • Southern Illinois University, School of Medicine
    • Indiana
      • Avon, Indiana, United States, 46123
        • American Health Network Institute, LLC
      • Fort Wayne, Indiana, United States, 46805
        • Fort Wayne Neurological Center
    • Kansas
      • Wichita, Kansas, United States, 67214
        • Via Christi Research
    • Massachusetts
      • Boston, Massachusetts, United States, 02115
        • Brigham and Womens Hospital; Center for Alzheimer Research & Treatment
      • Newton, Massachusetts, United States, 02459
        • Boston Center for Memory
    • Mississippi
      • Flowood, Mississippi, United States, 39232
        • Precise Research Centers
      • Jackson, Mississippi, United States, 39216
        • University of Mississippi Medical Center
    • Missouri
      • Bolivar, Missouri, United States, 65613
        • Missouri Memory Center
      • Saint Louis, Missouri, United States, 63110
        • Washington University School of Medicine
    • Nebraska
      • Omaha, Nebraska, United States, 68198-8440
        • University of Nebraska Medical Center; Dept of Neurological Sciences
    • Nevada
      • Las Vegas, Nevada, United States, 89106
        • Cleveland Clinic Lou Ruvo; Center for Brain Research
    • New Jersey
      • Springfield, New Jersey, United States, 07081
        • The Cognitive and Research Center of New Jersey
      • Toms River, New Jersey, United States, 08755
        • Advanced Memory Research Institute of NJ
    • New York
      • Lake Success, New York, United States, 11042
        • Neurological Associates of Long Island, PC
      • New York, New York, United States, 10032
        • Columbia University Medical Center
      • Rochester, New York, United States, 14620
        • AD-CARE, University of Rochester Medical Center
      • Staten Island, New York, United States, 10314
        • Richmond Behavioral Associates
      • Syracuse, New York, United States, 13210
        • SUNY Upstate Medical University
    • North Carolina
      • Charlotte, North Carolina, United States, 28211
        • Behavioral Health Research
      • Matthews, North Carolina, United States, 28105
        • Alzheimer's Memory Center
      • Raleigh, North Carolina, United States, 27607-6520
        • Raleigh Neurology Associates
      • Winston-Salem, North Carolina, United States, 27157
        • Wake Forest University
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Cleveland Clinic; Cleveland Lou Ruvo Center for Brain Health ? Neurological Institute
      • Columbus, Ohio, United States, 43210
        • Ohio State University; College of Medicine
    • Oregon
      • Portland, Oregon, United States, 97210
        • Summit Research Network Inc.
    • Pennsylvania
      • Abington, Pennsylvania, United States, 19001
        • Abington Neurological Associates
      • Jenkintown, Pennsylvania, United States, 19046
        • The Clinical Trial Center, LLC
    • Texas
      • Austin, Texas, United States, 78757
        • Senior Adults Specialty Research
      • Dallas, Texas, United States, 75231
        • Kerwin Medical Center
      • Dallas, Texas, United States, 75243
        • Neurology Consultants of Dallas; Research Department
      • Houston, Texas, United States, 77054
        • The University of Texas Health Science Center at Houston
      • Houston, Texas, United States, 77030
        • Alzheimers Disease & Memory Disorders Center; Department of Neurology Baylor College of Medicine
    • Utah
      • Salt Lake City, Utah, United States, 84107
        • Wasatch Clinical Research, LLC
    • Virginia
      • Charlottesville, Virginia, United States, 22906
        • University of Virginia
      • Norfolk, Virginia, United States, 23507
        • Sentara Neurology Specialists
      • Richmond, Virginia, United States, 23294
        • National Clinical Research Inc.-Richmond
    • Wisconsin
      • Madison, Wisconsin, United States, 53705
        • UW Wisconsin-Madison

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Completed Study WN29922 or WN39658, either its double-blind part or OLE part, and did not discontinue study drug early
  • The participant should be capable of completing assessments either alone or with the help of the caregiver
  • Availability of a person (referred to as the "caregiver")
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception methods with a failure rate of <1% per year (bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices) during the treatment period and for at least 16 weeks after the final dose of gantenerumab
  • Agreement not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug

Exclusion Criteria:

  • Pregnant or breastfeeding, or intending to become pregnant during the study or within at least 16 weeks after the final dose of study drug
  • Prematurely discontinued from Study WN29922 or WN39658
  • Any medical condition that may jeopardize the participant's safety if he or she continues to receive study treatment
  • Received any investigational treatment other than gantenerumab during or since completion of Study WN29922 or WN39658, either its double-blind or OLE part
  • Evidence of disseminated leptomeningeal hemosiderosis
  • Evidence of intracerebral macrohemorrhage
  • Use of prohibited medication
  • Evidence of ARIA-E on the last MRI scan report in Study WN29922 or WN39658, either its double-blind or OLE part

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group 1
Participants, who completed the double-blind part and did not enter the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the Week 116 visit of Study WN29922 or WN39658. This will be considered the OLE baseline visit (OLE Day 1).
Group 1 participants who were in the active arm in the double blind part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W. Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme before receiving target dose of open label gantenerumab, 510 mg SC, Q2W.
Group 2 participants who have completed OLE part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W
Experimental: Group 2
Participants, who completed the double-blind part and the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the OLE Week 34 visit or the final dose visit in the Study WN29922 or WN39658 OLE.
Group 1 participants who were in the active arm in the double blind part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W. Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme before receiving target dose of open label gantenerumab, 510 mg SC, Q2W.
Group 2 participants who have completed OLE part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: From Baseline (OLE Day 1) to Week 208
From Baseline (OLE Day 1) to Week 208
Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Score
Time Frame: From Baseline (OLE Day 1) to Week 208
From Baseline (OLE Day 1) to Week 208
Percentage of Participants with Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI)
Time Frame: From Baseline (OLE Day 1) to Week 208
From Baseline (OLE Day 1) to Week 208
Percentage of Participants with Amyloid-Related Imaging Abnormalities-Haemosiderin deposition (ARIA-H) Confirmed by MRI
Time Frame: From Baseline (OLE Day 1) to Week 208
From Baseline (OLE Day 1) to Week 208
Percentage of Participants with Injection-Site Reactions (ISRs)
Time Frame: From Baseline (OLE Day 1) to Week 208
From Baseline (OLE Day 1) to Week 208

Secondary Outcome Measures

Outcome Measure
Time Frame
Change in Clinical Dementia Rating (CDR) Score
Time Frame: From Baseline (OLE Day 1) to Week 208
From Baseline (OLE Day 1) to Week 208
Change in Mini-Mental State Examination (MMSE) Score
Time Frame: From Baseline (OLE Day 1) to Week 208
From Baseline (OLE Day 1) to Week 208
Change in Alzheimer Disease Assessment Scale-Cognition, Subscale 11 (ADAS-Cog11) Score
Time Frame: From Baseline (OLE Day 1) to Week 208
From Baseline (OLE Day 1) to Week 208
Change in Alzheimer Disease Assessment Scale-Cognition, Subscale 13 (ADAS-Cog13) Score
Time Frame: From Baseline (OLE Day 1) to Week 208
From Baseline (OLE Day 1) to Week 208
Change in Verbal Fluency Task Score
Time Frame: From Baseline (OLE Day 1) to Week 208
From Baseline (OLE Day 1) to Week 208
Change in Coding
Time Frame: From Baseline (OLE Day 1) to Week 208
From Baseline (OLE Day 1) to Week 208
Change in Functional Activities Questionnaire (FAQ) Score
Time Frame: From Baseline (OLE Day 1) to Week 208
From Baseline (OLE Day 1) to Week 208
Change in Alzheimer Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL) Score
Time Frame: From Baseline (OLE Day 1) to Week 208
From Baseline (OLE Day 1) to Week 208
Percentage of Participants with Anti-drug Antibody (ADA) to Gantenerumab
Time Frame: From Baseline (OLE Day 1) to Week 208
From Baseline (OLE Day 1) to Week 208

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma Concentration of Gantenerumab Administered SC
Time Frame: From Baseline (OLE Day 1) to Week 208
Re-classified as 'Other Pre-specified' due to sparse PK sampling, to support population PK analysis of the data which is an exploratory analysis.
From Baseline (OLE Day 1) to Week 208

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2021

Primary Completion (Actual)

March 6, 2023

Study Completion (Actual)

March 6, 2023

Study Registration Dates

First Submitted

May 1, 2020

First Submitted That Met QC Criteria

May 4, 2020

First Posted (Actual)

May 5, 2020

Study Record Updates

Last Update Posted (Actual)

March 28, 2023

Last Update Submitted That Met QC Criteria

March 24, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer Disease

Clinical Trials on Gantenerumab

3
Subscribe